This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit          July 16, 2015

Home  |   About SCAI  |   Membership  |   Education  |   Quality  |   Advocacy  |   Careers & Fellows  |   Press  |   Contact Us

 



In this issue...




SCAI NEWS

Early Bird Tuition for Complex Peripheral Vascular Interventions Extended to July 31
SCAI
Combining case-based learning — including review of your own cases — and simulation with the latest educational strategies SCAI's Complex Peripheral Vascular Interventions (CPVI) promises a fresh, innovative approach to your PVD education including:
  • Case-based, intensive focus on aorto-iliac Intervention, SFA intervention and critical limb ischemia;
  • Review of real cases starting weeks before the course;
  • Small groups coming together to present, discuss and solve cases;
  • Simulation training gives you a risk-free introduction to new techniques with experienced interventionalists on hand to offer tips and tricks;
  • Focus on latest data and guidelines from those who produced them;
  • Fun! This program will be interactive, social and unlike any other you've attended.
Best yet, the early bird tuition rate for CPVI has been extended to Friday, July 31.

Enroll now and save!

Acknowledgments

SCAI gratefully acknowledges the following companies for their generous support of the SCAI Complex Peripheral Interventions course through educational grants while taking sole responsibility for all content developed and disseminated through this event.
  • Silver sponsor: Medtronic, Terumo Interventional Systems
  • Bronze sponsors: Abbott; AstraZeneca, Cook Medical
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


PRODUCT SHOWCASE
  Global Interventional Medical Devices
Whether you are a healthcare professional, a patient or simply someone looking to know more about the complete solutions offered by Cordis, let us show you how our distinctive approach to working in partnership with you results in innovative interventional products and services to help support sustained patient outcomes.
 


SCAI, Specialty Medicine Partners Lauds House Passage of Bipartisan Bill on Healthcare Innovation
SCAI
SCAI recently joined its Alliance of Specialty Medicine partners in thanking the U.S. House of Representatives for passing HR 6, the 21st Century Cures Act, a bipartisan effort to improve the discovery, development and delivery that support continued innovation in our healthcare system. The Alliance looks forward to continuing to work with the Senate as they craft language for their Innovation for Healthier Americans initiative.

Find out more about this bill.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Who Will You Nominate for the Next MSCAI Class?
SCAI
The MSCAI designation was developed to recognize SCAI Fellows who have recognized by their peers as "having demonstrated excellence in Invasive/Interventional Cardiology over a career, manifested by a commitment to the highest levels of clinical care, innovation, publication and teaching." Once each year, a new group of Fellows will be awarded MSCAI status. SCAI Fellows may nominate themselves or be nominated by another SCAI Fellow. The 2015 online submission deadline is Oct. 31.

Nominate a colleague today!

View the current list of MSCAI.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  Coming July 2015 . . .
GLIDESHEATH SLENDER® 5Fr and 7Fr! The only family of unique thin-wall sheaths, offering radial access to more patients.

• Increase Your Radial Access Options • Optimize Procedural Outcomes • Preserve Arterial Function

*GLIDESHEATH SLENDER® is currently available in 6Fr.

©2015 Terumo Medical Corporation. All rights reserved. All brand names are trademarks or registered trademarks of Terumo. TIS-694-06012015
 


Looking to Reduce Your Transradial PCI Learning Curve?
SCAI
Researchers of a study published in Circulation concluded that adoption of the transradial PCI technique is related to issues concerning operator proficiency and the need to overcome the assumed learning curve.

The good news is that the learning curve is not as great as you'd imagine. Better yet, SCAI is here to help you tackle that learning curve with the launch of SCAI TRIP Online Curriculum.

Featuring the very best presentations from SCAI's popular Transradial Interventional Program (TRIP) Series, this all-new eLearning offering is available as a full course (eight CME credits) or by individual session (one CME credit each). You decide which sessions to take and when to take them based upon your busy schedule!

Whether you are starting a TRI program at your institution, simply looking to increase your proficiency or plan on tackling STEMI or peripheral procedures via radial access, this program will assist you in building on or expanding your skills.

Featuring the top transradial experts from throughout the U.S., this program will also demonstrate how transradial access can increase patient comfort and safety, lower bleeding complications and reduce healthcare costs. Other hot topics will include diagnostic and guide catheter selection.

Start tackling that learning curve today with TRIP Online Curriculum!

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Image of the Week: Why Can't I Advance Through the Prior Stent?

Emmanouil Brilakis, MD, PhD, FSCAI, of Dallas VA Medical Center and UT Southwestern Medical Center, recently presented a case illustrating the use of OCT to answer a mystery presenting in a routine angiographic follow-up nine months after right coronary artery PCI. Take a look at this case and send us your feedback!

Acknowledgments

The SCAI Imaging Center is developed and maintained with the generous support of St. Jude Medical. SCAI gratefully acknowledges this support, while taking sole responsibility for all content developed and disseminated through this effort.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




INDUSTRY NEWS


1 in 6 Americans Too Far From Lifesaving Heart Centers
HealthDay News
Tens of millions of rural, poor and Hispanic Americans do not have timely access to a lifesaving heart procedure, a new study finds. Researchers analyzed the driving times for 306 million people to reach the closest angioplasty centers across the continental United States. The median time to an angioplasty center was 33 minutes, they found. However, the median travel time for more than 16 percent of the population — about 50 million people — was 81 minutes, according to the study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The Vascular Team Approach: Getting a Leg Up on PAD With Education and Training
Cardiovascular Business
Interventional cardiologists are taking the lead in quality initiatives for peripheral artery disease revascularization. That includes developing guidelines, appropriate use criteria and promoting a vascular team model.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


FDA Strengthens Warning of Heart Attack and Stroke Risk for Nonsteroidal Anti-inflammatory Drugs
U.S. Food and Drug Administration
The U.S. Food and Drug Administration is strengthening an existing warning in prescription drug labels and over-the-counter drug facts labels to indicate that nonsteroidal anti-inflammatory drugs can increase the chance of a heart attack or stroke, either of which can lead to death. Those serious side effects can occur as early as the first few weeks of using an NSAID, and the risk might rise the longer people take NSAIDs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


An Interview With James Blankenship, MD, FSCAI
Cardiac Interventions Today
The newly inducted president of SCAI discusses what's ahead for the society during the next year, challenges with current healthcare policy and why he's an enthusiastic radialist.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


FDA Reports Serious Adverse Events With LARIAT Used for LAA Closure
Medscape
The U.S. Food and Drug Administration issued a safety communication to providers and patients regarding 45 patient deaths and other adverse events associated with SentreHEART devices used for left-atrial-appendage closure, including its LARIAT suture delivery device. The SentreHEART LARIAT and associated technologies have not been approved by the FDA for the prevention of thromboembolic stroke in patients with atrial fibrillation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


SCAI.15 From Atherectomies to Antiplatelets
Cardiovascular Business
Interventional Cardiology's annual meeting, SCAI 2015 Scientific Sessions, took place May 6-9 in San Diego. Here are some highlights from the late-breaking clinical trials.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Reopening the Book on Treating PVCs: More Evidence for PVC-HF Link
Medscape
A higher percentage of premature ventricular contractions predicted a drop-off in left ventricular ejection fraction and a greater risk of incident heart failure and mortality in a long-term follow-up of >1100 participants in a community-based study. All persons in the analysis had been older than 65 and free of heart failure with a normal left ventricular ejection fraction at baseline when they underwent 24-hour Holter monitoring for PVC assessment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PCSK9 Inhibitors Versus the Guidelines
MedPage Today
VideoBrief With cardiovascular disease prevention guidelines controversially having dropped lipid targets in 2013 and instead emphasizing statins for all at-risk people with elevated levels, where does a new class fit that dramatically lowers low-density lipoproteins beyond what statins can do? The two PCSK9 inhibitors recommended for approval by U.S. Food and Drug Administration advisers last month — evolocumab (Repatha) and alirocumab (Praluent) — have cut low-density lipoproteins by an absolute 30 to 60 percent from baseline across trials, either on top of a statin or alone depending on the population.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Registry Data Challenge CABG Survival Advantage in Diabetics Versus PCI Using Contemporary Stents
Medscape
In patients with diabetes mellitus and multivessel disease, percutaneous coronary intervention with a current-generation stent is associated with a lower risk of death and stroke in early follow-up but an equivalent risk of death and a higher rate of myocardial infarction and need for repeat revascularizations in the long term when compared with coronary artery bypass graft surgery. These are the main findings from an analysis of more than 16,000 patients included in the New York state percutaneous coronary intervention and cardiac surgery registries.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The Summer of Cardiology Blockbusters?
MedPage Today
U.S. Food and Drug Administration approval of heart failure drug sacubitril/valsartan (Entresto), previously known as LCZ696, and the pending approval of two PCSK9 inhibitors this summer has reinvigorated the search for further advances in cardiology, experts said. Pharmacologic findings with major impact on clinical practice have otherwise been sparse, noted Milton Packer, MD, chair of clinical sciences at UT Southwestern in Dallas and lead researcher on the PARADIGM-HF trial of LCZ696.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Cardiology Today Offers Resource Featuring Top Findings, Clinical Perspectives From the SCAI Scientific Sessions
Healio
Cardiology Today has released an interactive online supplement that compiles top research from the annual Society for Cardiovascular Angiography and Interventions Scientific Sessions in San Diego and offers expert perspectives to put key findings into context for practitioners. This resource covers encouraging data revealed on the combination of blood pressure and cholesterol therapies to reduce coronary plaque in the MILLION study, as well as the transition off dual antiplatelet therapy with cilostazol in the OUTSIDE START study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


ONLINE JOB BOARD

Job Title Employer Location
Interventional Cardiology Cejka Search Terre Haute, IN
RN Tenet Healthcare Hialeah, FL
PA HCA - The Healthcare Company Wichita, KS

For a complete list of job postings, click here.
To post your resume, click here.


CALENDAR OF EVENTS

Date Event Location
Aug. 1-2 SCAI Fellows Course at LWSIC Chandigarh, INDIA
Aug. 5-7 SCAI TAVR Session @ SOLACI Mexico City, MEXICO
Aug. 22-23 SCAI China Fellows Course Kaifeng, CHINA
Sept. 25-26 SCAI CPVI - Complex Peripheral Vascular Interventions Washington, D.C.
Oct. 29-31 SCAI at Great Wall International Congress of Cardiology Beijing, CHINA
Nov. 13-15 SCAI Fellows Course at AICT 2015 Dhaka, BANGLADESH
Dec. 6-9 SCAI 2015 Fall Fellows Courses Las Vegas
Feb. 25 SCAI Session at CardioEgypt 2016 Cairo, EGYPT
May 4-7, 2016 SCAI 2016 Scientific Sessions Orlando, FL

CLICK HERE for a full calendar of SCAI events


The news summaries appearing in SCAI This Week are based on original information from news organizations and are produced by Multibriefs, an independent e-mail newsletter publisher. SCAI is not responsible for the content of sites external to SCAI, nor do reports in SCAI This Week constitute the official opinion of SCAI. The SCAI This Week news roundup is provided as a timely update for SCAI members and other healthcare professionals. Links to articles are provided for readers' convenience and may be of use in discussions with patients or colleagues. Questions and comments about SCAI This Week may be directed to Multibriefs at scai@multibriefs.com.


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Poor Mobility Strongly Predicts Mortality in TAVR Patients (TCTMD)
'Breakthrough' Heart Failure Drug Wins Speedy Approval (MedPage Today)
SCAI 2015 On Demand: Summer School for the Cath Lab (SCAI)
Another PFO Closure Study Yields Mixed Migraine Results (Medscape)

Don't be left behind. Click here to see what else you missed.


 



SCAI This Week
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Katina Smallwoood, Senior Content Editor, 469.420.2675 
Contribute news

Learn how to add us to your safe sender list so our emails get to your inbox.

This edition of SCAI This Week was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 9, 2015
July 2, 2015
June 25, 2015
June 18, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063